Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.
The Philadelphia biotech’s seed financing was led by Columbus Venture Partners and will help Tolerance push its programs toward the clinic, according to an Oct. 15 release.
The company is developing therapies that center around the thymus, an organ in the chest that creates white blood cells, or “the master regulator of immune tolerance,” according to the biotech.
Tolerance touts an allogeneic thymus induced pluripotent stem cell (iPSC)-based cell therapy platform, plus other thymus-targeting therapies to address immune-mediated diseases caused by abnormalities in immune tolerance. These conditions include cancer, autoimmunity, transplant rejection, infections, immune deficiencies and allergies, according to the company.
More specifically, Tolerance’s tech aims to prevent thymic changes and restore thymic function.
“We intend to rapidly advance and validate…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Quantinuum Announces Pricing of Upsized Initial Public Offering
BROOMFIELD, Colo., June 3, 2026 /PRNewswire/ — Quantinuum Inc. (“Quantinuum”) today announced the pricing of the upsized initial public offering of 28,000,000 shares of its Class A common stock at a price to the public […]
Why Does Chronic Back Pain Make Everyday Sounds Feel Harsher? Brain Imaging Study Points to a Treatable Cause
People with chronic back pain process everyday sounds differently, and more intensely, than people without pain, according to new research from the University of Colorado Anschutz. Click here to view original post Click Here to […]
How Can Fluoride Help or Hurt Your Teeth?
Imagine walking down the street and seeing half of those who pass by missing all their teeth. Sixty years ago, that was the norm, when 50% of Americans 65 and older had lost all their […]
